Puma Biotech (PBYI) Tops Q3 EPS by 13c, Misses on Revenue

Puma Biotech (NASDAQ: PBYI) reported Q3 EPS of $0.46, $0.13 better than the analyst estimate of $0.33. Revenue for the quarter came in at $80.5 million versus the consensus estimate of $70.65 million.

For earnings history and earnings-related data on Puma Biotech (PBYI) click here.

You May Also Be Interested In

• BrightSpring Health Services, Inc. (BTSG) Tops Q2 EPS by 24c ; Offers Guidnce
• Samsung Electronics Co Ltd. (005930:KS) (SSNLF) PT Raised to KRW490,000 at Goldman Sachs
• BTIG Downgrades Upbound Group (UPBD) to Neutral